While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.

Pfizer acquired Seagen in 2023 for $43 billion, and shut down construction on a $350 million manufacturing facility the ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only as a combination therapy.

Tuckner’s discovery is reminiscent of a 2019 analysis that found browser extensions installed on 4 million browsers collected ...

We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.

In a move that might allow them to sell drugs directly to patients, some drugmakers are getting into the telehealth business.